Dynavax Technologies Co. (NASDAQ:DVAX) VP David Louis Johnson sold 3,092 shares of the business’s stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $18.60, for a total value of $57,511.20. Following the sale, the vice president now owns 7,780 shares of the company’s stock, valued at approximately $144,708. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Dynavax Technologies Co. (NASDAQ:DVAX) opened at $18.50 on Monday. The company has a market capitalization of $1,121.03, a P/E ratio of -9.49 and a beta of 1.31. Dynavax Technologies Co. has a 52-week low of $3.70 and a 52-week high of $24.45.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.15. The firm had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.28 million. Dynavax Technologies had a negative return on equity of 65.97% and a negative net margin of 1,177.60%. Dynavax Technologies’s revenue for the quarter was down 68.8% on a year-over-year basis. During the same period in the previous year, the company posted ($0.90) EPS. research analysts anticipate that Dynavax Technologies Co. will post -1.72 EPS for the current year.

A number of analysts have recently issued reports on the company. ValuEngine cut Dynavax Technologies from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Royal Bank of Canada reiterated an “outperform” rating and set a $28.00 target price (up previously from $26.00) on shares of Dynavax Technologies in a report on Monday, September 25th. BidaskClub cut Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. Cantor Fitzgerald boosted their target price on Dynavax Technologies from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Thursday, November 9th. Finally, Cowen reiterated a “buy” rating and set a $30.00 target price on shares of Dynavax Technologies in a report on Friday, November 3rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $25.17.

A number of institutional investors have recently added to or reduced their stakes in DVAX. Russell Investments Group Ltd. lifted its position in Dynavax Technologies by 24.0% during the 2nd quarter. Russell Investments Group Ltd. now owns 155,095 shares of the biopharmaceutical company’s stock worth $1,496,000 after acquiring an additional 30,036 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in Dynavax Technologies by 77.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 181,161 shares of the biopharmaceutical company’s stock worth $1,749,000 after acquiring an additional 79,141 shares in the last quarter. Rhumbline Advisers lifted its position in Dynavax Technologies by 35.5% during the 2nd quarter. Rhumbline Advisers now owns 60,503 shares of the biopharmaceutical company’s stock worth $584,000 after acquiring an additional 15,865 shares in the last quarter. State of Wisconsin Investment Board acquired a new position in Dynavax Technologies during the 2nd quarter worth approximately $328,000. Finally, Bank of New York Mellon Corp lifted its position in Dynavax Technologies by 41.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 250,862 shares of the biopharmaceutical company’s stock worth $2,421,000 after acquiring an additional 73,866 shares in the last quarter. 70.54% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Dynavax Technologies Co. (DVAX) VP Sells $57,511.20 in Stock” was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/dynavax-technologies-co-dvax-vp-sells-57511-20-in-stock/1798441.html.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with Analyst Ratings Network's FREE daily email newsletter.